14.02.2020 - 14:17 Uhr

Xlife Sciences AG: Capital Increase 'Private Placement'

Xlife Sciences AG, CH0461929603

Xlife Sciences AG: Capital Increase 'Private Placement' Based on the resolution of the Board of Directors on 14th of February 2020 (resolution of the general assembly on 25th of October 2018), Xlife Sciences AG has decided to execute a "private placement" from authorized capital, 260'000 shares at a share price of CHF 33.50.- (EUR 30.70.-, average share price over the 30 last trading days, EUR/CHF average rate ESTV 1.0912). Xlife Sciences AG will direct more investments towards employees in research and development. In addition, the project portfolio will be further diversified.

Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

14-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Xlife Sciences AG Klausstrasse 19 8008 Zürich

Switzerland Phone: 0041 44 385 84 60 E-mail: info@xlifesciences.ch Internet: www.xlifesciences.ch ISIN: CH0461929603 WKN: A2PK6Z Listed: Regulated Unofficial Market in Munich EQS News ID: 975861   End of Announcement DGAP News Service

975861  14-Feb-2020 CET/CEST